NEW Own ABBV? Track every ABBV payout — and your other stocks

Track your stocks, dividends, monitor DRIP shares, and project your passive income.

Start Free »

AbbVie Inc. ABBV | NYSE

$256.34 $0.00 | 0.00%

Next Earnings: Sep 04, 2026

Company Overview:

Market Cap: $0

Trailing PE: 0x

FWD PE *: 16.9x

Payout Ratio (TTM): 189.6%

52-Week Range: $190.75 - $267.47

* Forward PE is based on street estimates.

10 Year ABBV Performance Metrics:

Total Return (with DRIP): 491.5% (19.45% CAGR)

Total Return (no DRIP): 374.8% (16.86% CAGR)

Share Price: 299.8% (14.86% CAGR)

Yield on Cost (with DRIP): 15.97%

Total Invested: $10,000

Total Value (with DRIP): $59,155

Total Return $ (with DRIP): $49,155

Dividend Increase: 170.3% (10.73% CAGR)

Dividend Yield (FWD): 2.70% ($6.92)

ABBV 10-yr Total Return ($10K invested)

1Y 2Y 5Y 10Y All

ABBV Share Price chart

Share Price

ABBV Price CAGR:1Y: 20.35%2Y: 14.07%5Y: 18.09%10Y: 14.86%

ABBV Dividend Charts

ABBV - Dividends

ABBV Dividend CAGR:1Y: 5.49%2Y: 5.65%5Y: 5.88%10Y: 11.74%

ABBV - Dividend Payout Ratio

ABBV - Dividend to Free Cash Flow Ratio

Unlock All Reports & Research Dividend Stocks.

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $128.25/yr ($10.69/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Start Free Trial

You save $99.75 (44%)

ABBV Earnings, Revenue, Cash & Debt, Shares Outstanding:

ABBV - Revenue

ABBV Revenue CAGR:1Y: 10.16%2Y: 8.39%5Y: 4.01%10Y: 10.17%

ABBV - Earnings Per Share (EPS)

ABBV EPS CAGR:1Y: 283.02%2Y: 61.32%5Y: 37.04%10Y: 7.55%

ABBV - Net Income

🔒 Unlock

ABBV Net Income CAGR:1Y: 285.50%2Y: 62.46%5Y: 36.40%10Y: 8.43%

ABBV - EBITDA

🔒 Unlock

ABBV EBITDA CAGR:1Y: 65.70%2Y: 19.95%5Y: 1.62%10Y: 10.40%

ABBV - Free Cash Flow

🔒 Unlock

ABBV Free Cash Flow CAGR:1Y: -36.24%2Y: 23.85%5Y: -7.88%10Y: 5.71%

ABBV - Free Cash Flow / Share

🔒 Unlock

ABBV Free Cash Flow / Share CAGR:1Y: -24.18%2Y: 34.95%5Y: -4.67%10Y: 6.62%

ABBV - Operating Income

🔒 Unlock

ABBV Operating Income CAGR:1Y: 37.37%2Y: 29.68%5Y: 8.65%10Y: 10.91%

ABBV - Gross Profit

🔒 Unlock

ABBV Gross Profit CAGR:1Y: 14.64%2Y: 11.25%5Y: 6.12%10Y: 9.67%

ABBV - Shares Outstanding

🔒 Unlock

ABBV Shares Outstanding CAGR:1Y: -0.06%2Y: 0.00%5Y: -0.06%10Y: 0.82%

ABBV - Share Buybacks

🔒 Unlock

ABBV Share Buybacks CAGR:1Y: -25.00%2Y: 0.00%5Y: -2.09%10Y: -45.37%

ABBV - Stock-Based Comp

🔒 Unlock

ABBV Stock-Based Comp CAGR:1Y: -7.26%2Y: -12.74%5Y: 0.87%10Y: 8.86%

ABBV - Expenses

🔒 Unlock

ABBV Expenses CAGR:1Y: -1.49%2Y: 4.86%5Y: 6.33%10Y: 7.30%

ABBV - Revenue vs Net Income

🔒 Unlock

ABBV - EPS vs FCF / Share

🔒 Unlock

ABBV - EPS vs PE Ratio

🔒 Unlock

ABBV - FCF vs FCF / Share

🔒 Unlock

ABBV - FCF vs Stock Based Comp

🔒 Unlock

ABBV - Cash & Debt

🔒 Unlock

ABBV - Revenue by Segment

🔒 Unlock

ABBV Revenue CAGR:1Y: 10.16%2Y: 8.39%5Y: 4.01%10Y: 10.17%

ABBV - Revenue by Region

🔒 Unlock

ABBV Revenue CAGR:1Y: 10.16%2Y: 8.39%5Y: 4.01%10Y: 10.17%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

ABBV - REVENUE: Actual + Estimates

🔒 Unlock

ABBV Actual Revenue CAGR:1Y: 10.16%2Y: 8.39%5Y: 4.01%10Y: 10.17%

ABBV - EPS: Actual + Estimates

🔒 Unlock

ABBV Actual EPS CAGR:1Y: 283.02%2Y: 61.32%5Y: 37.04%10Y: 7.55%

ABBV - NET INCOME: Actual + Estimates

🔒 Unlock

ABBV Actual Net Income CAGR:1Y: 285.50%2Y: 62.46%5Y: 36.40%10Y: 8.43%

ABBV - EBITDA: Actual + Estimates

🔒 Unlock

ABBV Actual EBITDA CAGR:1Y: 65.70%2Y: 19.95%5Y: 1.62%10Y: 10.40%

Ratios, Profit Margins & Return on Capital:

ABBV - Net Profit Margin

🔒 Unlock

ABBV Net Profit Margin CAGR:1Y: 249.84%2Y: 49.87%5Y: 31.11%10Y: -1.58%

ABBV - Gross Profit Margin

🔒 Unlock

ABBV Gross Profit Margin CAGR:1Y: 4.07%2Y: -6.20%5Y: 2.03%10Y: -0.45%

ABBV - Price to Earnings

🔒 Unlock

ABBV - Price To Sales Ratio

🔒 Unlock

ABBV - Return on Capital Employed

🔒 Unlock

ABBV - Return on Invested Capital

🔒 Unlock

ABBV Dividends Info:

Annual Dividend: $6.92

Forward Yield: 2.7%

Ex-Dividend Date: 2026-07-15

Lifetime Dividends / Share: $57.42

ABBV Dividend History: Dates, Payments & Yield list

Below is a schedule of all ABBV dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield

Ex-Date	Payment Date	Amount	Yield	Forward Yield	Price on Ex-Date
07/15/2026	08/14/2026	$1.730	2.83%	2.77%	$249.46
04/15/2026	05/15/2026	$1.730	3.32%	3.29%	$210.39
01/16/2026	02/17/2026	$1.730	3.23%	2.97%	$232.86
10/15/2025	11/14/2025	$1.640	2.9%	2.82%	$232.36
07/15/2025	08/15/2025	$1.640	3.52%	3.17%	$206.69
04/15/2025	05/15/2025	$1.640	3.71%	3.61%	$181.68
01/15/2025	02/14/2025	$1.640	3.83%	3.4%	$192.87
10/15/2024	11/15/2024	$1.550	3.23%	3.76%	$164.99
07/15/2024	08/15/2024	$1.550	3.69%	3.21%	$193.40
04/12/2024	05/15/2024	$1.550	3.82%	3.79%	$163.79
01/12/2024	02/15/2024	$1.550	3.82%	3.51%	$176.59
10/12/2023	11/15/2023	$1.480	3.99%	4.3%	$137.60
07/13/2023	08/15/2023	$1.480	4.43%	3.89%	$152.12
04/13/2023	05/15/2023	$1.480	3.64%	4.04%	$146.59
01/12/2023	02/15/2023	$1.480	3.89%	3.92%	$151.06
10/13/2022	11/15/2022	$1.410	3.95%	3.69%	$153.04
07/14/2022	08/15/2022	$1.410	3.75%	3.96%	$142.29
04/13/2022	05/16/2022	$1.410	3.55%	3.63%	$155.47
01/13/2022	02/15/2022	$1.410	4.22%	3.9%	$144.76
10/14/2021	11/15/2021	$1.300	4.77%	4.45%	$116.84
07/14/2021	08/16/2021	$1.300	4.43%	4.39%	$118.41
04/14/2021	05/14/2021	$1.300	4.91%	4.47%	$116.43
01/14/2021	02/16/2021	$1.300	4.66%	4.99%	$104.20
10/14/2020	11/16/2020	$1.180	5.48%	4.8%	$98.36
07/14/2020	08/14/2020	$1.180	4.77%	4.96%	$95.07
04/14/2020	05/15/2020	$1.180	5.75%	5.2%	$90.71
01/14/2020	02/14/2020	$1.180	5.35%	5.02%	$94.05
10/11/2019	11/15/2019	$1.070	5.81%	4.83%	$88.63
07/12/2019	08/15/2019	$1.070	6.09%	6.8%	$62.98
04/12/2019	05/15/2019	$1.070	5.3%	5.43%	$78.78
01/14/2019	02/15/2019	$1.070	5.05%	5.29%	$80.85
10/12/2018	11/15/2018	$0.960	4.23%	4.26%	$90.14
07/12/2018	08/15/2018	$0.960	4.02%	3.94%	$97.45
04/12/2018	05/15/2018	$0.960	4.17%	3.69%	$104.18
01/11/2018	02/15/2018	$0.710	2.86%	2.47%	$114.90
10/12/2017	11/15/2017	$0.640	2.8%	2.73%	$93.76
07/12/2017	08/15/2017	$0.640	3.56%	3.64%	$70.34
04/11/2017	05/15/2017	$0.640	3.99%	3.84%	$66.67
01/11/2017	02/15/2017	$0.640	4.19%	4.15%	$61.65
10/12/2016	11/15/2016	$0.570	3.72%	3.63%	$62.87
07/13/2016	08/15/2016	$0.570	3.52%	3.38%	$67.39
04/13/2016	05/16/2016	$0.570	3.86%	3.65%	$62.45
01/13/2016	02/16/2016	$0.570	4.45%	4.26%	$53.51
10/13/2015	11/16/2015	$0.510	3.79%	3.4%	$60.01
07/13/2015	08/14/2015	$0.510	2.93%	2.97%	$68.65
04/13/2015	05/15/2015	$0.510	3.33%	3.09%	$65.99
01/13/2015	02/13/2015	$0.490	3.09%	3.38%	$58.05
10/10/2014	11/17/2014	$0.420	3.06%	2.58%	$65.04
07/11/2014	08/15/2014	$0.420	3.06%	3.12%	$53.90
04/11/2014	05/15/2014	$0.420	3.62%	3.19%	$52.69
01/13/2014	02/14/2014	$0.400	3.21%	3.15%	$50.73
10/10/2013	11/15/2013	$0.400	3.5%	3.3%	$48.44
07/11/2013	08/15/2013	$0.400	3.65%	3.7%	$43.21
04/11/2013	05/15/2013	$0.400	3.7%	3.48%	$46.03
01/11/2013	02/15/2013	$0.400	4.73%	4.26%	$37.58

Projected Future Returns & Dividends for ABBV

Based on past 10-year performance, here are ABBV growth metrics:

Share price CAGR of +14.86%
Dividend CAGR of +11.75%

Using ABBV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, is modelled to grow as follows:

	ABBV (DRIP)	ABBV - No DRIP
Current Price	$256.34	$256.34
Start Shares	39.01	39.01
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	51.05	39.01
Dividends Payment	$4.49	$4.49
Annual Dividends	$916	$700
Yield on cost	9.16%	7.00%
Share Price	$664.88	$664.88
Total Dividends	$5,023	$4,302
Final Value	$33,945	$30,240

Estimated Future Value + Dividends - ABBV

NOTE: Above numbers are our estimate based on ABBV's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $128.25/yr ($10.69/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Start Free Trial

You save $99.75 (44%)

Company Info

AbbVie Inc. (ABBV) had its IPO on 2013-01-02, and is trader on NYSE stock exchange.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

ABBV website: https://www.abbvie.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $128.25/yr ($10.69/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Start Free Trial

You save $99.75 (44%)